Protocol Ledger

NCT04908787 · Phase III · COMPLETED

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Interventional Phase III clinical trial protocol NCT04908787 sponsored by Jiangsu Simcere Pharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-11 Enrollment: 421 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04908787
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)421 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04908787
Protocol FieldVerified Registry Value
NCT IdentifierNCT04908787
Consolidated Lead SponsorJiangsu Simcere Pharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment421 participants (ACTUAL)
Registered Start Date2021-06-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI